More Actions
PharmacokineticsRLSRLS GuidelinesPHNDosingSavingsSummary

The Horizant® Difference

Extended Release for Continued Relief1,2

The difference is everything

  • Only gabapentin approved for moderate-to-severe Restless Legs Syndrome (RLS) and Postherpetic Neuralgia (PHN)1,3,4
  • Once-daily dosing for RLS, single-step titration for PHN1,a
  • Gabapentin enacarbil (Horizant®) is the ONLY FDA-approved treatment for RLS that is strongly recommended by the American Academy of Sleep Medicine (AASM) Clinical Practice Guidelines5,b

aPlease see dosing for specific patient populations. For patients with renal impairment, geriatric use, and use with CNS depressants, please see dosing in the full Prescribing Information.

bStrong recommendation moderate certainty of evidence; based on 8 randomized controlled trials and 3 observational studies.5

See what makes Horizant® unique

Horizant® is not interchangeable with other gabapentin products.1

The clinical significance of the PK data for Horizant® and gabapentin is unknown.